Combining PARP inhibition with PD-1 inhibitors

Affiliations

Comment

Ulrik Lassen. Lancet Oncol. 2019 Sep.

. 2019 Sep;20(9):1196-1198.

doi: 10.1016/S1470-2045(19)30509-1. Epub 2019 Aug 1.

¹ Department of Oncology, Rigshospitalet, 2100 Copenhagen, Denmark. Electronic address: ulrik.lassen@regionh.dk.

No abstract available

Comment on

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M, Lundy J, Freimund A, Norris C, Mu S, Wu J, Paton V, Gao B. Friedlander M, et al. Lancet Oncol. 2019 Sep;20(9):1306-1315. doi: 10.1016/S1470-2045(19)30396-1. Epub 2019 Aug 1. Lancet Oncol. 2019. PMID: 31378459 Clinical Trial.